Table 4.
Proportion of impaired domains
| % impaired domains |
Aβ-pos
(n = 44) |
stableAβ-neg
(n = 30) |
progAβ-neg
(n = 25) |
|---|---|---|---|
| n (%) | n (%) | n (%) | |
| 0 | 10 (21%) | 16 (47%) | 6 (23%) |
| 1–25 | 12 (26%) | 9 (26%) | 7 (27%) |
| 26–50 | 12 (26%) | 6 (18%) | 10 (38%) |
| 51–75 | 9 (19%) | 3 (9%) | 3 (12%) |
| 76–100 | 4 (9%) | 0 | 0 |
Aβ-pos = amyloid-positive; stableAβ-neg = stable amyloid-negative and progAβ-neg = progressive amyloid-negative.
Number of patients in each group with impairment (i.e. SS ≤ 4) in 0, 1–25%, 26–50%, 51–75% or 76–100% of the domains assessed.